Table 5:

Clinico-pathologic characteristics of patients who received renal allografts from donors with APOL1 high-risk genotypes

Subjects	Patient #8	Patient #11	Patient #12	Patient #14	Patient #25	Patient #27	Patient #35	Patient #37	Patient #38
Donor race	Hispanic	AA	AA	AA	AA	AA	AA	AA	AA
Allograft source	L	D	D	D	D	D	D	L	D
APOL1 testing specimen	Post-rep	Post-rep	Non- infl Bx	Post-rep	Blood	Blood	Post-rep	Blood	Blood
Post-transplant interval to biopsy (days)	602	173	653	86	423	229	505	1489	425
Concurrent comorbidities, namely AR, viral infection, or acute VOD	AR	AR	AR	AR	Prior AR Prior CMV	CMV	AR	AR	Prior CMV
Serum Cr at biopsy (mg/dL)	9.7	2.5	6.5	7.2	5.5	6.4	1.7	7.9	5.2
Urine protein/Cr at biopsy (g/g)	3.8	2.2	6.9	2	3.5	15	6	11.6	7.6
Collapsed glomeruli (%)	31	13	17	15	13	33	28	12	25

- Abbreviations: AA, African American; AR, acute rejection; Cr, creatinine; D, deceased donor; L, living donor; Non-infl Bx, non-inflamed biopsy performed at 1 month post-transplantation; Post-rep: post-reperfusion biopsy, VOD, vaso-occlusive disease

- Recipient #25 and #38 received their allografts from the same donor

Recipients #25 had CMV infection 230 days before index biopsies which persisted till 217 days before index biopsy and a biopsy with borderline changes 209 days prior to index biopsy

Recipients #38 had CMV infection 71 days before index biopsies which persisted till 57 days before index biopsy